Summary:
Tralokinumab monotherapy for treating moderate-to-severe atopic dermatitis
Qualified Participants Must:
Have moderate to severe atopic dermatitis covering 10% of their bodies or more
Be 18 years of age or older
Qualified Participants May Receive:
Free study related care and treatment; compensation for their time and travel